Worth reading
27Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
2
LocationWording
Conditional
How definitive the wording is.This transaction
Acquisition of a business (dispensing pharmacies)Counterparty (target company)株式会社ファインズファルマ
Disclosing companyMedical Ikkou Group Co.,Ltd.
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
Dispensing pharmacies, drugstores, and EC shop operations
Location 6-36 Hiroji-Honmachi, Showa-ku, Nagoya, Aichi PrefectureShare capital ¥10 millionDate of incorporation November 2005
Net SalesNot disclosed following discussions with the counterparty
Operating profitNot disclosed following discussions with the counterparty
Net income for the current fiscal yearNot disclosed following discussions with the counterparty
Net assetsNot disclosed following discussions with the counterparty
Impact on Business Performance
Immaterial
| Item | Details |
|---|---|
| Transaction name | Acquisition of a business (dispensing pharmacies) |
| Counterparty name | 株式会社ファインズファルマ |
| Name of the Subject Company | 株式会社ファインズファルマ |
| Business Description of the Subject Company | Dispensing pharmacies, drugstores, and EC shop operations |
| Location of the Subject Company | 6-36 Hiroji-Honmachi, Showa-ku, Nagoya, Aichi Prefecture |
| Capital Stock of the Subject Company | ¥10 million |
| Date of Establishment of the Subject Company | November 2005 |
| Net Sales of the Subject Company | Not disclosed following discussions with the counterparty |
| Operating Profit of the Subject Company | Not disclosed following discussions with the counterparty |
| Net Income of the Subject Company | Not disclosed following discussions with the counterparty |
| Net Assets of the Subject Company | Not disclosed following discussions with the counterparty |
| Impact on Business Performance | Immaterial |
| Date of board resolution | 24 June 2026 |
| Contract Date | 30 June 2026 (scheduled) |
| Execution Date / Effective Date | 1 August 2026 (scheduled) |
Items this document does not state (17)
Acquisition priceExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Valuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The acquisition is intended to support further growth in the dispensing pharmacy business and strengthen the Company’s operating base. The Company also intends to carry on the trust and track record of the 2 pharmacies and contribute to the development of community healthcare.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.